Cell Carcinoma Clinical Trial
Official title:
Establishment and Application of 3-Dimensional (3-D) Cell Culture Model of Clinical Circulating Tumor Cells (CTCs)
NCT number | NCT05623748 |
Other study ID # | 202101222A3 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 31, 2021 |
Est. completion date | May 31, 2024 |
The goal of this observational study is to validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion in cancer patient with transitional cell carcinoma and patient without cancer. This project first aims to study the clinical feasibility of utilizing a 3-D cell culture model for the isolation/purification of all possible CTCs in a blood sample in a label-free, viable, and high-purity manner. Through 3-D CTC culture, moreover, the cell number of CTCs can be adequately expanded. All these advantageous features are beyond what is currently possible by using the existing methods. In addition, the harvest of CTCs with above features is found valuable for the subsequent academic researches or clinical studies (e.g. molecular mechanisms underlying cancer metastasis, cancer-related gene mutation, biomarker discovery, and particularly CTCs-based chemotherapy drug testing). These could both facilitate and accelerate scientists to develop new therapeutic solutions for future cancer care.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | May 31, 2024 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: 1. patients who agreed with the content of informed consent of the study protocol 2. patients who agreed the researcher to review the medical record 3. adults >20 years old 4. Patients have the right to asked withdrawing from the trial at any timepoints 5. meet the following requirements (1)cancer participants:cancer patients with transitional cell carcinoma (2)healthy participants:participants without cancer Exclusion Criteria: 1. Patients who refused the collection of blood and the reviewing of medical record 2. The investigators suggest to withdraw |
Country | Name | City | State |
---|---|---|---|
Taiwan | Chang Gung Memorial Hospital | New Taipei City |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Taiwan,
Konstantopoulos K, Thomas SN. Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng. 2009;11:177-202. doi: 10.1146/annurev-bioeng-061008-124949. — View Citation
Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006 Jun;6(6):449-58. doi: 10.1038/nrc1886. — View Citation
Oppenheimer SB. Cellular basis of cancer metastasis: A review of fundamentals and new advances. Acta Histochem. 2006;108(5):327-34. doi: 10.1016/j.acthis.2006.03.008. Epub 2006 May 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the effect of cell culture model for the Cell viability | optimize the 3-D cell culture model to measure the Cell viability | baseline | |
Primary | the effect of cell culture model for the Cell viability | optimize the 3-D cell culture model to measure the Cell viability | 3 month | |
Primary | the effect of cell culture model for the Cell viability | optimize the 3-D cell culture model to measure the Cell viability | 6 month | |
Primary | the effect of cell culture model for the Cell number | optimize the 3-D cell culture model to measure the Cell number | baseline | |
Primary | the effect of cell culture model for the Cell number | optimize the 3-D cell culture model to measure the Cell number | 3 month | |
Primary | the effect of cell culture model for the Cell number | optimize the 3-D cell culture model to measure the Cell number | 6 month | |
Secondary | the effect of biochemical factors for glucose concentration | investigate the effect of of biochemical factors to measure glucose concentration | baseline, pre-intervention | |
Secondary | the effect of biochemical factors for glucose concentration | investigate the effect of of biochemical factors to measure glucose concentration | 3 month | |
Secondary | the effect of biochemical factors for glucose concentration | investigate the effect of of biochemical factors to measure glucose concentration | 6 month | |
Secondary | the effect of biochemical factors for the serum concentration of growth factors/cytokines | investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines | baseline, pre-intervention | |
Secondary | the effect of biochemical factors for the serum concentration of growth factors/cytokines | investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines | 3 month | |
Secondary | the effect of biochemical factors for the serum concentration of growth factors/cytokines | investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines | 6 month | |
Secondary | the effect of biochemical factors for the serum pH | investigate the effect of of biochemical factors to measure the serum pH | baseline | |
Secondary | the effect of biochemical factors for the serum pH | investigate the effect of of biochemical factors to measure the serum pH | 3 month | |
Secondary | the effect of biochemical factors for the serum pH | investigate the effect of of biochemical factors to measure the serum pH | 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04821128 -
Radio/Pathological Evaluation of Tongue Cancer Infiltration
|
||
Recruiting |
NCT06112522 -
Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
|
Phase 2 |